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BACKGROUND: In singleton pregnancies, studies investigating cell- rate was 0.31%. The mean fetal fraction was 12.2% (range, 3%e36%); all
free DNA in maternal blood have consistently reported high detection
rate and low false-positive rate for the 3 common fetal trisomies (trisomies
21, 18, and 13). The potential advantages of noninvasive prenatal testing
in twin pregnancies are even greater than in singletons, in particular lower
need for invasive testing and consequent fetal loss rate. However, several
organizations do not recommend cell-free DNA in twin pregnancies and
call for larger prospective studies.
OBJECTIVE: In response to this, we undertook a large prospective
multicenter study to establish the screening performance of cell-free DNA
for the 3 common trisomies in twin pregnancies. Moreover, we combined
our data with that reported in published studies to obtain the best estimate
of screening performance.
STUDY DESIGN: This was a prospective multicenter blinded study
evaluating the screening performance of cell-free DNA in maternal plasma
for the detection of fetal trisomies in twin pregnancies. The study took place
in 6 fetalmedicine centers in England, United Kingdom. The primary outcome
was the screening performance and test failure rate of cell-free DNA using
next generation sequencing (the IONA test). Maternal blood was taken at the
time of (or after) a conventional screening test. Data were collected at
enrolment, at any relevant invasive testing throughout pregnancy, and after
delivery until the time of hospital discharge. Prospective detailed outcome
ascertainment was undertaken on all newborns. The study was undertaken
and reported according to the Standards for Reporting of Diagnostic Accu-
racy Studies. A pooled analysiswas also undertaken using our data and those
in the studies identified by a literature search (MEDLINE, Embase, CENTRAL,
Cochrane Library, and ClinicalTrials.gov) on June 6, 2020.
RESULTS: A total of 1003 women with twin pregnancies were recruited,
and complete data with follow-up and reference data were available for 961
(95.8%); 276 were monochorionic and 685 were dichorionic. The failureCite this article as: Khalil A, Archer R, Hutchinson V,
et al. Noninvasive prenatal screening in twin pregnancies
with cell-free DNA using the IONA test: a prospective
multicenter study. Am J Obstet Gynecol
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https://doi.org/10.1016/j.ajog.2021.01.0059 samples with a 3% fetal fraction provided a valid result. There were no
false-positive or false-negative results for trisomy 21 or trisomy 13, whereas
there was 1 false-negative and 1 false-positive result for trisomy 18. The
IONA test had a detection rate of 100% for trisomy 21 (n¼13; 95% con-
fidence interval, 75e100), 0% for trisomy 18 (n¼1; 95% confidence in-
terval, 0e98), and 100% for trisomy 13 (n¼1; 95% confidence interval,
3e100). The corresponding false-positive rates were 0% (95% confidence
interval, 0e0.39), 0.10% (95% confidence interval, 0e0.58), and 0% (95%
confidence interval, 0e0.39), respectively. By combining data from our
study with the 11 studies identified by literature search, the detection rate for
trisomy 21 was 95% (n¼74; 95% confidence interval, 90e99) and the
false-positive rate was 0.09% (n¼5598; 95% confidence interval,
0.03e0.19). The corresponding values for trisomy 18 were 82% (n¼22;
95% confidence interval, 66e93) and 0.08% (n¼4869; 95% confidence
interval, 0.02e0.18), respectively. There were 5 cases of trisomy 13 and
3881 nonetrisomy 13 pregnancies, resulting in a computed average
detection rate of 80% and a false-positive rate of 0.13%.
CONCLUSION: This large multicenter study confirms that cell-free
DNA testing is the most accurate screening test for trisomy 21 in twin
pregnancies, with screening performance similar to that in singletons and
very low failure rates (0.31%). The predictive accuracy for trisomies 18
and 13 may be less. However, given the low false-positive rate, offering
first-line screening with cell-free DNA to women with twin pregnancy is
appropriate in our view and should be considered a primary screening test
for trisomy 21 in twins.
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Many health systems offer routine ante-
natal screening for trisomy 21 (Down
syndrome), which is the most common
chromosomal abnormality at birth. In
the first trimester of pregnancy,
screening tests available include ultra-
sound measurement of the fetal nuchal
translucency and other sonographic
markers, to which measurement of
maternal serum free beta human chori-
onic gonadotropin and pregnancy-
associated plasma protein A can beMONTH 2021 Amadded (the “combined test”). More
recently, cell-free DNA (cfDNA) in
maternal blood has been either utilized
as a first-line screening test or offered to
women who after combined screening
demonstrate an intermediate or high
chance (in contingent screening)1 or a
high chance (in secondary screening).2
In singleton pregnancies, the com-
bined test has a detection rate (DR) for
trisomy 21 of 90% and a false-positive
rate (FPR) of 5%.3 The chief advan-
tages of cfDNA screening are a highererican Journal of Obstetrics & Gynecology 1.e1
AJOG at a Glance
Why was this study conducted?
National and international guidelines highlighted that the total number of re-
ported affected cases in studies reporting on the predictive accuracy of cell-free
DNA for common trisomies in twins is small and called for more studies.
Key findings
The screening performance of noninvasive prenatal testing for trisomy 21 in twin
pregnancies is similar to what is reported in singletons. However, the predictive
accuracy for trisomies 18 and 13 may be less.
What does this add to what is known?
This prospective multicenter study included nearly 1000 twin pregnancies and
reported very low failure rate (<0.5%) and excellent predictive accuracy for tri-
somy 21. The detection rate for trisomy 21 according to pooled data from 5598
twin pregnancies and 74 cases of trisomy 21 is 95% for a false-positive rate of
0.1%.
Original Research OBSTETRICS ajog.orgassociatedDRof 99.7% (95% confidence
interval [CI], 99.1e99.9) and much
lower FPR of 0.04% (95% CI,
0.02e0.07), which translates into a
much lower need for invasive testing and
consequent fetal loss rate.4
In principle, these advantages of
cfDNA screening should be greater still in
twins: this is because the incidence of
trisomy 21 is higher in twin than
singleton pregnancies5 and because
combined screening in twin pregnancies
has a lower DR (75%) and higher FPR
(9% of pregnancies and 7% of fetuses).6
This high FPR is of particular concern
because pregnancy loss rates after invasive
prenatal diagnosis are higher in twin
pregnancies7e9 and because of the addi-
tional complexity of selective termination
of pregnancy, an option that is given
when there is discordance between fetuses
in any abnormality, which carries addi-
tional risks to the ongoing pregnancy.10
However, there is greater uncertainty
regarding the predictive accuracy of
cfDNA in twin pregnancies than that of
singleton pregnancies.10 Studies in sin-
gletons are very large, with a recent
meta-analysis including 1963 cases of
trisomy 21 and 223,932 of nonetrisomy
21, 563 cases of trisomy 18 and 222,013
unaffected pregnancies, and 119 cases of
trisomy 13 and 212,883 unaffected
pregnancies.4 In contrast, data in twin
pregnancies are much scarcer. A recent
meta-analysis included only 7 studies, 561.e2 American Journal of Obstetrics & Gynecologycases with trisomy 21 and 3718
nonetrisomy 21 twin pregnancies, 18
cases of trisomy 18 and 3143
nonetrisomy 18 pregnancies, and 3
affected cases with trisomy 13. The
respective pooled weighted DR and FPR
were 98.2% (95% CI, 83.2e99.8) and
0.05% (95% CI, 0.01e0.26) for trisomy
21 and 88.9% (95% CI, 64.8e97.2) and
0.03% (95% CI, 0.00e0.33) for trisomy
18, whereas for trisomy 13, based on just
3 cases, DR was 66.7% and FPR was
0.19%. It is of note that screening char-
acteristics in the individual studies
included varied: for trisomy 21, the DR
ranged from 94.1% and 100% and FPR
between 0% and 0.24%, whereas for
trisomy 18, the DR was from 50.0% and
100% and FPR between 0% and 0.10%
(the numbers for trisomy 13 are too
small to report).
A lower screening performance of
cfDNA testing in twin pregnancies may
be expected biologically because of a
number of factors. Aneuploidy in dizy-
gotic twins is likely to affect only 1 fetus;
however, the cfDNA contribution of the
2 fetuses can vary up to 2-fold.11,12 In
addition, the fetal fraction of cfDNA in
the maternal circulation is lower in
singleton pregnancies when the fetus is
affected by trisomy 21,13 and this is likely
also true in dizygotic twin pregnancies
discordant for aneuploidy, so that a high
contribution from a normal cotwin
could “mask” the low fetal fraction of theMONTH 2021affected fetus, leading to a false-negative
result. This challenge in the use of
cfDNA in dizygotic twin pregnancies
could explain the higher failure rate
(almost double) in dichorionic than
monochorionic twins.14 Moreover,
other factors known to be associated
with a lower fetal fraction in singleton
pregnancies include in vitro fertilization
(IVF) conception and higher maternal
weight, 2 factors that are more common
in twin than singleton pregnancies.13
In part owing to these concerns on the
small number of twin pregnancies
affected by common trisomies that are
reported in the published literature, na-
tional guidelines call for more data on
the performance of screening by cfDNA
testing in twin pregnancies.15 In
response to this, we undertook a large,
prospective, multicenter study to estab-
lish the screening performance of cfDNA
testing for the 3 common fetal trisomies
(trisomies 21, 18, and 13) in twin preg-
nancies and to assess the performance of
the test in different types of twin preg-
nancies including dizygotic dichorionic,
monozygotic dichorionic, and mono-
zygotic monochorionic. Finally, we
combined our data from those available
in the literature to obtain the best esti-
mate of screening performance based on
the totality of the evidence.
Methods
This is a prospective, multicenter study
evaluating the screening characteristics
of measurement of maternal cfDNA in
maternal plasma samples, obtained from
women with a twin pregnancy, for the
detection of fetal trisomies. The study
was undertaken in 6 fetal medicine
centers in England: St George’s Univer-
sity Hospitals NHS Foundation Trust,
Leicester Royal Infirmary, the Central
Manchester University Hospitals NHS
Foundation Trust, Norfolk and Norwich
University Hospitals NHS Foundation
Trust, Leeds General Infirmary, and John
Radcliffe Hospital in Oxford, United
Kingdom. Participants were recruited
between February 2015 and June 2018.
The study was undertaken and reported
according to the 2015 Standards for
Reporting of Diagnostic Accuracy
Studies.16
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Eligible women were at least 16 years old
with fetal ultrasound demonstrating a
viable twin pregnancy of at least 10
weeks’ gestation and were considered
able to give their informed consent and
not from a vulnerable group. The defi-
nition of vulnerable group was in
accordance with ISO14155:2020 and
excluded the following subjects: partici-
pants who have Down syndrome or
other chromosomal abnormality them-
selves, children under 16 years old,
adults with learning disabilities or
mental illness or who are unable to give
informed consent for themselves, adults
who are unconscious or very severely ill,
adults who have a terminal illness or
current malignancy, adults in emergency
situations, prisoners and young of-
fenders, or any person considered to
have a particularly dependent relation-
ship with investigators. The exclusion
criteria included higher order multiple
pregnancies, fetal demise or vanishing
twin, known mosaicism, partial trisomy
or translocations, or known aneuploidy
or malignancy in the pregnant woman.
After providing a written informed
consent, participating women provided
a blood sample at the time of (or after) a
conventional screening test, such as
combined test, quadruple serum
screening, screening ultrasound scan, or
other clinically available cfDNA test. We
included 2 groups of pregnant women
with twin pregnancies: the first group
consisted of those with a low chance of
carrying a fetus with a chromosomal
abnormality, on the basis of the con-
ventional prenatal screening tests; the
second group included women with a
high chance, on the basis of conventional
prenatal screening tests (in the United
Kingdom, this is defined as greater than
1:150 at term), and who attended the
fetal medicine clinics at the study sites
for prenatal counseling and possible
diagnostic testing (chorionic villus
sampling [CVS] or amniocentesis).
Information was collected at subject
recruitment and included demographic
characteristics (maternal age, parity,
height, weight) and current pregnancy
history (method of conception,screening test results, relevant ultra-
sound findings, chorionicity, estimated
due date, and gestational age at blood
sampling). Data collection forms were
completed at enrolment, at any relevant
invasive testing throughout pregnancy,
and at follow-up (delivery and until the
time of hospital discharge). Prospective
detailed outcome ascertainment was
undertaken on all newborns at each
center, including birth outcome, the
presence of any congenital abnormal-
ities, phenotypic appearance at birth,
and any chromosomal testing under-
taken in the antenatal or immediate
postnatal period (such as CVS, amnio-
centesis, or postnatal cord blood
testing). For birth outcome, where
newborn examination results were not
available directly, data were obtained
from referring hospitals or through
direct contact with the participant.
There were 103 cases where amniocen-
tesis was performed and 12 who had
CVS, whereas the birth outcomes were
obtained by newborn examination, from
data from referring hospitals, or directly
from mother or birth outcome in 846
participants.
The test laboratory staff were blinded
to any ultrasound or clinical test results,
including the karyotype. Test results of
cfDNA testing weremade available to the
clinicians managing the pregnant
women participants.
Test characteristics
All tests were undertaken using the
IONA test, using next generation
sequencing, and using a proprietary al-
gorithm. The IONA test was Conformité
Européenne (CE) marked in February
2015 for the screening of trisomies 21,
18, and 13 by using a sample of maternal
blood, which contains fragments of
cfDNA from both the placenta and the
mother. A CE mark (CE marking, which
represents regulatory approval of a
medical device in the United Kingdom
and Europe) is placed onmedical devices
to show they conform to the re-
quirements in the directives. It shows
that the device is fit for its intended
purpose stated and meets legislation
relating to safety. Although consideredMONTH 2021 Amvalidated for use in twin pregnancies in
the Instructions for Use, only 11 twin
pregnancies were included in the vali-
dation study for CE marking, all of
which were correctly assayed.17
Cell-free DNA preparation and
sequencing
At each site, peripheral maternal blood
(10 mL) was collected into standard
Streck blood sample tubes from each
participant. The samples were then sent
to a central laboratory (Yourgene Health
Clinical Service Laboratory, Manchester,
United Kingdom) to be tested for tri-
somies 21, 18, and 13 using the IONA
test. Samples were initially processed to
isolate cfDNA and prepared for
sequencing following methods detailed
by Crea et al.18 On arrival at the central
laboratory, the maternal blood samples
were centrifuged at 1600 grams for 10
minutes and the plasma fraction
removed; this was then centrifuged for a
further 10 minutes at 16,000 grams to
remove any cellular material. Unless
analyzed on the same day as being
received, the plasma samples were held
at 80C. Samples were either analyzed
on the day of arrival or held frozen, for
up to a week if insufficient samples were
available to make up an analysis run.
Before analysis, the plasma sample was
defrosted and centrifuged for 1minute at
3000 grams. The resultant cfDNA was
isolated, extracted, and sequenced from
1.0 to 2.5 mL of maternal plasma, which
contained both maternal and fetal
cfDNA. The cfDNA was extracted using
an automated DNA extraction platform
(QIAsymphony, QIAGEN, Hilden, Ger-
many) and used for DNA library prep-
aration using the IONA Library
Preparation Kit in combination with an
automated liquid handling platform
(Sciclone, PerkinElmer Inc, Waltham,
MA). The IONA run control DNA li-
brary was included to ascertain the val-
idity of the sequencing run performed.
Semiconductor whole-genome
sequencing was performed using Ion
Chef and Ion Proton systems (Thermo
Fisher Scientific, Waltham, MA), ac-
cording to the manufacturer’s in-
structions, as a multiplex of 8 samples inerican Journal of Obstetrics & Gynecology 1.e3
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sequencing runs per day were performed
to achieve the 32-sample optimal
throughput). The assessment of fetal
fraction was made using a proprietary
method developed by Premaitha Health.
All sample processing and analysis
were performed by appropriately trained
and experienced operators who were
blinded to karyotype results throughout
the study. The IONA test results were
compared with the results from invasive
testing or birth outcome.
Primary outcomes and clinical
reference standard
The primary outcome measures of the
study were the screening performance of
the IONA test in terms of DR and spec-
ificity in twin pregnancies for each of the
3 trisomies and the test failure rate. This
was considered important to overcome
the challenge encountered in the use of
cfDNA in twin pregnancies. The refer-
ence test (gold standard) was chromo-
somal analysis undertaken prenatally
(CVS or amniocentesis) or postnatally
(umbilical cord or newborn blood) or
the absence of phenotypic features for
chromosomal abnormalities after birth.
Ethical approval
This multicenter study was approved by
the ethics committee of South Berkshire
B. All women gave a written informed
consent to participate. Subjects were free
to withdraw from participation in this
study at any time for any reason without
affecting their standard of care. The
study was registered on ClinicalTrials.
gov with the registration number
NCT03200041.
Systematic review
To determine the predictive accuracy of
cfDNA analysis for trisomies 21, 18, and
13 in twin pregnancy based on the to-
tality of evidence, the study results were
combined with those results identified in
a review of the literature (Supplemental
Table).19e29 We searched MEDLINE,
Embase, CENTRAL, Cochrane Library,
and ClinicalTrials.gov on June 6, 2020, to
identify published cohort studies on the
performance of maternal cfDNA testing
for trisomies 21, 18, and 13 in twin1.e4 American Journal of Obstetrics & Gynecologypregnancy. We included studies in which
data on pregnancy outcome were pro-
vided for at least 85% of the study pop-
ulation. Data on the number of
pregnancies, chorionicity, gestational
age at sampling, method of analyzing
samples, DR, and FPR were extracted
from these studies.
Statistical analysis
The resulting fragment count data from
each sample were used as input to a set of
mixture models that incorporate distri-
butions of expected values under both
trisomy-affected and trisomy-unaffected
hypotheses for trisomies 21, 18, and 13.
Each model generated a test likelihood
ratio that was then used, together with
maternal ageederived previous proba-
bility of trisomy, to quantify the proba-
bility of each trisomy, taking into
account both maternal age and the cor-
responding DNA test result. In this way,
the IONA software interprets the results,
so the pipeline generates a final result
without the need for further local bio-
informatics analysis. The software used
for analysis in the IONA test includes
entry of multiple pregnancy status
(singleton or twin) and chorionicity
(monochorionic, dichorionic, or un-
known) for every sample. In the event of
a twin pregnancy which is not known to
be monochorionic, an inbuilt validity
check algorithm is modified. A twin
correction factor is applied which effec-
tively increases the minimum fetal frac-
tionwhichmust be reached for the check
to pass. This accounts for the possibility
that 1 of the 2 fetuses in a dichorionic
twin pregnancy could be trisomy
affected, with the other fetus being un-
affected, a situationwhich could lead to a
reduced trisomy chromosome level
measurement for the pregnancy as a
whole. The correction also accounts for
the fact that in trisomy 18 and 13 affected
pregnancies, lower levels of trisomy
chromosome measurements may occur.
This extra correction further increases
the required minimum fetal fraction for
the check to pass.
To investigate the performance of the
IONA test, we calculated DR, specificity,
failure rates, and CIs for aneuploidy and
euploid twin pregnancies.MONTH 2021For the pooled analysis, we calculated
the DR and FPR with corresponding
95% CI for individual studies and the
pooled DR and FPR using random-effect
meta-analyses. Between-study heteroge-
neity was assessed using the I2 statistic.
The analyses were stratified according to
the type of aneuploidy (trisomy 21 or
trisomy 18). Because there were a very
small number of cases of trisomy 13 for a
meaningful pooled analysis, we
computed average DR and FPR values.
Statistical analyses were performed using
the StatsDirect statistical software
(version 2.7.8, StatsDirect Ltd, Cheshire,
United Kingdom).
Sample size considerations
The sample size estimate in singleton
pregnancies calculated that samples
from 92 pregnancies complicated by
trisomy 21 and 738 euploid fetuses were
required.17 However, this took into ac-
count the numbers needed for assay
robustness studies, in-use optimization
studies, and sample stability studies,
which have since been established and
therefore did not require repetition.
Furthermore, at the time of planning,
the largest study reporting data on the
use of cfDNA in twin pregnancies
included 515 twin pregnancies (351 with
known outcomes, 12 cases of trisomy
21). Owing to the rarity of aneuploidy
and on the basis of sample sizes utilized
to support existing noninvasive prenatal
testing (NIPT) testing claims, the study
design presented was to target 15 cases
affected by trisomy; this was more than
the existing literature claimed at the time
of study design and included unaffected
samples in excess of the population
prevalence to maximize chances of
obtaining sufficient trisomy cases and
accounting for “loss to follow-up” at a
rate of 15%. The initial aim for this study
was to include 350 euploid twin preg-
nancies and 15 pregnancies with 1 or
both fetuses affected by trisomy 21. To
achieve this, the plan was to recruit 500
subjects pregnant with twins, approxi-
mately 350 twin pregnancies at a low
chance of aneuploidy (based on con-
ventional screening methods), and at
least 150 high-chance twin pregnancies
confirmed by prenatal invasive
FIGURE
Study flowchart
The study took place in 6 United Kingdom centres and enrolled 1003 twin pregnancies; 961 (685
dichorionic and 276 monochorionic) had results available for analysis and 958 were included in the
final analysis.
T13, trisomy 13; T18, trisomy 18; T21, trisomy 21.
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However, at interim analysis, a smaller
than expected number of women with a
high chance of trisomy 21 were identi-
fied; to reach our target number of 15
trisomy 21 affected pregnancies, the
number of subjects to be recruited was
increased to 1000 twin pregnancies
(2000 fetuses).
Results
During the study, we enrolled 1003
women and samples were collected from
all study participants meeting the entry
criteria. Complete data with follow-up
and reference data (chromosomal anal-
ysis or birth outcome) were available for
961 of women (95.8%) because 37
women were lost to follow-up and a
further 5 patients were excluded (4 did
not meet the inclusion criteria and 1
patient withdrew from the study). The
results from all remaining 961 patient
samples were available for analysis and
assessment of clinical accuracy. In the
population, there were 16 chromosomal
abnormalities, comprising 14 with tri-
somy 21 and 1 each with trisomy 18 and
trisomy 13 (Figure).
The mean gestational age at enrolment
was 15weeks and 6 days (ranging from 10
to 36 weeks), and the mean maternal age
was 32.4 years (range, 17e60 years). In
260 patients, the pregnancy was the result
of IVF treatment (Table 1). Cases in
which cfDNA screening was performed
before 20 weeks’ gestation and at or
greater than 20 weeks’ gestation are pre-
sented in Supplemental Figures 1 and 2,
respectively.
Of the 961 samples available for
analysis, 276 of the twin pregnancies
were monochorionic and 685 were
dichorionic. A breakdown of the initial
screening results, per fetus, found 1129
of the fetuses had a low chance of tri-
somies 21, 18, and 13, whereas 793 had a
high chance; the breakdown is presented
in Table 2.
Of the 961 women included in the
final patient sample, 958 samples
generated a result from the IONA test,
whereas in 3 cases the samples failed to
generate a result, a failure rate of 0.31%.
All 3 were followed up and subsequently
found to have normal chromosomes in 2cases and trisomy 21 (as determined on
CVS) in 1 case. The fetal fraction in the
analyzed samples ranged from 3% to
36% (median, 13.7%) in dichorionic
twins and 4% to 29% (median, 11.6%)
in monochorionic twins; the 9 samples
with 3% fetal fraction provided a valid
result. Samples that failed to generate a
result were excluded from the DR and
screening characteristics, to better
distinguish between “no calls” (caused
through events such as machine break-
down or insufficient fetal fraction within
a sample) and the alternative of a false-
negative or false-positive result, where a
result is obtained using the test but is in
disagreement with the birth outcome or
amniocentesis result. “No calls” are re-
ported as a failed test percentage; in
practice, these are reported back to the
healthcare provider to ensure that
counseling is given regarding the options
(such as a blood sample redraw, other
form of screening, or invasive testing).MONTH 2021 AmThe DR and specificity of the test,
based on the 958 women with a result,
and the results are presented in Table 3.
Of note is that, compared with the
reference test, there were no false-
positive or false-negative results for tri-
somy 21 or trisomy 13. For trisomy 18,
there was 1 false-negative and 1 false-
positive result. The false-negative result
occurred with a likelihood ratio of 5.3
and a background chance of 1:2301
resulting in an adjusted chance of 1:435,
which was considered screen negative.
The algorithm of the test has since been
amended to include an additional sam-
ple validity check for cases where
maternal age risk is low (<1:150) and the
likelihood ratio is small and positive; this
sample would no longer produce a false-
negative result. The false-positive result
was associated with a likelihood ratio of
74 and a background chance of 1:174,
which resulted in adjusted chance of
1:33.erican Journal of Obstetrics & Gynecology 1.e5
TABLE 1
Baseline characteristics and pregnancy history in the study population
(n[961) and pregnancy outcomes of the 1922 fetuses
Characteristic Median (IQR), mean (SD), or n (%)
Maternal age, y 33 (31e38)
Gestational age at blood draw, wk 14.1 (12.7e18.7)
Maternal weight, kg 72 (39e168)
Maternal height, cm 163.5 (6.6)
Maternal body mass index, kg/m2 25.1 (22.2e29.0)
Maternal blood transfusion within 6 mo 6 (0.6)
Previous pregnancy with aneuploidy 16 (1.7)
Conception by IVF 245 (25.5)
Monochorionic twin pregnancy 276 (28.8)
Dichorionic twin pregnancy 685 (72.2)
Fetal fraction, % 11 (8e15)
Live birth 1804 (95.9)
Intrauterine fetal death 41 (2.1)
Termination of pregnancy 31 (1.6)
Miscarriage 46 (2.4)
Number recruited in the first trimestera 223 (23.2)
Number recruited in the second trimestera 685 (71.3)
Number recruited in the third trimestera 53 (5.5)
IQR, interquartile range; IVF, in vitro fertilization; SD, standard deviation.
a Of the 16 aneuploid cases, 13, 2, and 1 were diagnosed in the first, second, and third trimester, respectively.
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TABLE 2
Previous screening results and indications leading to cell-free DNA testing
Indications Number of patients
Maternal age of >35 y as the sole indication 560
No specific indication (“routine” screening) 168
Ultrasound findings 106
High-chance combined test result 59
Previous chromosomal abnormality 26
High-chance quadruple test result 14
Nuchal translucency of 3.5 mm 14
Nuchal translucency of 3.5 and ultrasound findings 6
Ultrasound findings and previous chromosomal abnormality 2
Ultrasound findings and high-chance NIPT result 2
Nuchal translucency of 3.5 and previous chromosomal abnormality 1
High-chance previous NIPT test result 1
Other 2
NIPT, noninvasive prenatal testing.
Khalil et al. Cell-free DNA in twins. Am J Obstet Gynecol 2021.
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The literature search identified 11 rele-
vant studies, excluding potentially
overlapping studies (Supplemental
Table). In the combined populations
of our study and the 11 studies identi-
fied by the literature search, there were
74 cases of trisomy 21 and 5598
nonetrisomy 21 twin pregnancies, 22
cases of trisomy 18 and 4869
nonetrisomy 18 pregnancies, and 5
cases of trisomy 13 and 3881
nonetrisomy 13 pregnancies. Overall,
73 of 74 pregnancies with trisomy 21
were detected using cfDNA, giving a
pooled DR of 95% (95% CI, 90e99)
and FPR of 0.09 (95% CI, 0.02e0.19)
(Table 4). The DR of cfDNA for trisomy
18 was 82% (95% CI, 66e93) and FPR
was 0.08 (95%CI, 0.02e0.18) (Table 5).
Because there were a very small number
of cases of trisomy 13 for meaningful
pooled analysis, we computed average
DR and FPR values; these were 80% and
0.13%, respectively. The main limita-
tions of previous studies were the small
sample size, retrospective design, and
use of stored samples (Videos 1 and 2).
Discussion
Summary of the study findings
The performance of cfDNA analysis of
maternal blood for trisomies 21, 18, and
13 in twin pregnancy was investigated in
a large, prospective multicenter study in
the United Kingdom which recruited
more than 1000 pregnancies. There was
a very low failure rate for cfDNA testing,
with only 3 cases where results could not
be obtained. All cases of trisomy 21 and
the 1 case of trisomy 13 were detected
with an FPR of 0%. For trisomy 18, there
was 1 false-positive and 1 false-negative
result giving a DR of 0% (95% CI, 0%
e97%) in which the 95% CI is much
wider for twins owing to the small
number of cases available.
Interpretation of study findings and
comparison with existing literature
Our findings of high predictive accuracy
of cfDNA for trisomy 21 in twins similar
to that reported in singleton pregnancies
are consistent with the published studies
and pooled analysis.26 DRs obtained in
this study are equivalent to those shown
TABLE 3
Screening characteristics for trisomies 21, 18, and 13 in the study
Trisomy Affected True positive Unaffected True negative False positive Sensitivity, % (95% CI) Specificity, % (95% CI)
Trisomy 21 13 13a 945a 945 0 100 (75e100) 100 (99.6e100)
Trisomy 18 1 0 957a 956 1 0 (0e97) 99.9 (99.4e100)
Trisomy 13 1 1 957a 957 0 100 (3e100) 100 (99.6e100)
CI, confidence interval.
Data are expressed as number unless noted otherwise.
a Three samples, 2 unaffected and 1 trisomy 21, were excluded from the screening characteristics because they failed to provide a test result that could be compared for concordance with the
reference method. These samples form the basis of the test failure rate that is reported for this study as 0.31%.
Khalil et al. Cell-free DNA in twins. Am J Obstet Gynecol 2021.
ajog.org OBSTETRICS Original Researchin the pooled literature review which
suggests consistently high performance.
This is likely because the minimal
requirement for fetal fraction in twins is
increased compared with singleton
pregnancies to prevent the reporting of
wrong results and to ensure sufficient
fetal material is present within the sam-
ple. This test has been designed to
maintain the performance level as seen
with singleton pregnancies but expects
to return a higher failure rate corre-
sponding to the need for higher fetal
fraction. Although this study was not
powered to investigate this and achievedTABLE 4




Lau et al,19 2013 1
Huang et al,20 2014 9
Tan et al,21 2016 4
Du et al,22 2017 2
Le Conte et al,23 2018 3
Yang et al,24 2018 4
Yu et al,25 2019 16
Gil et al,26 2019 17
Garshasbi et al,27 2020 3
Motevasselian et al,28 2020 1





Khalil et al. Cell-free DNA in twins. Am J Obstet Gynecol 2very low failure rates, we believe the
findings to be consistent with this
approach. Because the study cohort
included only 1 pregnancy affected by
trisomy 13, no firm conclusions could be
drawn from this study on the screening
performance for trisomy 13. The FPR for
trisomy 18 is consistent with previous
studies,26 and it is suggested that such
false-positive result could be caused by
cotwin demise,30 confined placental
mosaicism,31 maternal mosaicism,32
malignancy,33 and uniparental dis-
omy.24 None of these factors were iden-






1 100 (3e100) 11
9 100 (66e100) 180
4 100 (40e100) 506
2 100 (16e100) 89
3 100 (29e100) 415
4 100 (40e100) 396
16 100 (79e100) 1141
16 94 (71e100) 980
3 100 (29e100) 440
1 100 (3e100) 355
1 100 (3e100) 140
13 100 (75e100) 945
73 95 (90e99) 5598
0
021.
MONTH 2021 AmMoreover, sex chromosome analysis
was not included in the screening algo-
rithm owing to limited clinical utility in
singletons or twins and owing to ethical
constraints related to the risk of selective
sex-specific termination. Screening for
sex aneuploidy is also not recommended
by the National Screening Committee in
the United Kingdom.
Clinical and research implications
In this study, the results could not be
obtained in only 3 cases. Previous studies
have identified dichorionicity as a risk



















erican Journal of Obstetrics & Gynecology 1.e7
TABLE 5
Studies reporting on screening for trisomy 18 using cell-free DNA in twin pregnancy
Study
Trisomy









Huang et al,20 2014 2 1 50 (1e99) 187 0 0 (0e1.95)
Le Conte et al,23 2018 1 1 100 (3e100) 417 0 0 (0e0.88)
Yang et al,24 2018 1 1 100 (3e100) 399 0 0 (0e0.92)
Yu et al,25 2019 4 4 100 (40e100) 1153 0 0 (0e0.32)
Gil et al,26 2019 10 9 90 (55e100) 987 1 0.10 (0e0.56)
Garshasbi et al,27 2020 1 1 100 (3e100) 442 0 0 (0e0.83)
Motevasselian et al,28 2020 2 2 100 (16e100) 354 0 0 (0e1.04)
Current study 1 0 0 (0e98) 957 1 0.10 (0e0.58)
Pooled analysis 22 19 82 (66e93) 4869 2 0.08 (0.02e0.18)
Heterogeneity (I2) 1.6 0
CI, confidence interval.
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Original Research OBSTETRICS ajog.orghave estimated that cfDNA test failure
after first sampling in dichorionic twins
to be 3.3 times higher than in singletons.
The authors reported that this is likely to
be attributed to the higher incidence of
IVF conception and nulliparity among
twin pregnancies than singletons. Given
the very low failure rate in this study, it
was not possible to examine risk factors
of failed cfDNA.
Initial reports on the performance of
screening for trisomy 21 by cfDNA in
twin pregnancies are encouraging, and
therefore, the American College of Ob-
stetricians and Gynecologists has rec-
ommended its use.15 Similarly, other
guidelines focusing on twin pregnancies,
such as those by the International Soci-
ety of Ultrasound in Obstetrics and Gy-
necology and the Royal College of
Obstetricians and Gynaecologists,35,36
have acknowledged the potential role of
cfDNA as a screening tool for trisomy 21
in twin pregnancies and highlighted the
need for more studies to validate its
performance.
Although the focus of some guidelines
is on the possible lower DR in twins than
singletons, we believe that is an irrele-
vant comparison for pregnant women.
Rather, the data are of importance when
it comes to the choice of screening test.
Our data, combined with those in the
existing literature, show that there is now1.e8 American Journal of Obstetrics & Gynecologystrong evidence that cfDNA is more ac-
curate than the combined test or second
trimester serum biochemistry in twin
pregnancy.35,36 In our opinion, perhaps
the most important advantage is the
much lower FPR of cfDNA in twin
pregnancies than other tests: the FPR in
combined screening is high (9% of
pregnancies and 7% of fetuses),6 and this
means that consideration for invasive
testing is relevant in 1 in 11 twin preg-
nancies. A meta-analysis published in
2012 suggests that overall pregnancy loss
rates after invasive prenatal diagnosis are
considerable7e9 (3.8% and 3.1% after
CVS and amniocentesis)7; this is
certainly higher than in singleton preg-
nancies, where the loss rates have
recently been shown to be lower than
previously estimated.37 Of note, the
most recent meta-analysis that included
16 studies and performed a head-to-
head comparison between twin preg-
nancies undergoing and those not un-
dergoing invasive testing demonstrated
that there was no difference in the risk of
fetal loss. The pooled incidence of fetal
loss in twin pregnancies undergoing
CVS was 2.0% (compared with 1.8%)
and in those undergoing amniocentesis
was 2.4% (compared with 2.4%).38
Finally, combined screening for aneu-
ploidy in twin pregnancy is more com-
plex than that in singletons: additionalMONTH 2021factors to be considered include
chorionicity-related predictive accuracy
and the option of selective termination
of pregnancy, which carries additional
risk to the ongoing pregnancy.10,35
Strengths and weaknesses
Our study is one of the largest twin
studies investigating the performance of
cfDNA analysis of maternal blood for
trisomies 21, 18, and 13 in twin preg-
nancy. Despite this, 1 limitation was the
relatively small number of pregnancies
affected with trisomies. However, this
reflects the nature of the low prevalence
of trisomies 21, 18, and 13 and the fact
that the study included a mainly low-
chance population for aneuploidy.
The strengths of this study include the
prospective multicenter design with
input from the patient and public rep-
resentatives in the content of the study
documents, study publicity, interpreta-
tion of study findings, and dissemination
of study findings.
The cfDNA test was performed and
the results were given by the laboratory
without previous knowledge of the fetal
karyotype or pregnancy outcome. We
report detailed methodology and labo-
ratory techniques used. The algorithm
for assessment takes into account
maternal age and fetal fraction while
calculating the likelihood ratio.
ajog.org OBSTETRICS Original ResearchMoreover, the study included pregnan-
cies with both low and high chances on
previous screening, which reflects clin-
ical practice, ensuring its generalizability.
Furthermore, the loss to follow-up rate
was low, further reducing the risk of bias.
Finally, the study results were com-
bined with those identified in a review of
the literature, and therefore, it is possible
to present the most up-to-date summary
of the performance of cfDNA analysis of
maternal blood for trisomies 21, 18, and
13 in twin pregnancy (Supplemental
Table, Table 4, and Table 5).
It is important to highlight the fact
that the DRs only apply to the twin cases
that received results. Routine imple-
mentation of NIPT needs to take into
account the test failure rate (which at the
time of the first draw was 3.4% in sin-
gletons, 4.9% in monochorionic twins,
and 11.3% in dichorionic twins),35
although it was much lower in our
study (0.31%). Furthermore, studies
report on the screening performance at a
wide gestational age window, beyond 16
weeks’ gestation in a number of the
studies with some testing performed as
late as 36 weeks’ gestation, making this
less clinically relevant. Moreover, cfDNA
is unable to predict which twin is
affected. Therefore, nuchal translucency
and detailed ultrasound scan have a po-
tential role in suggesting which twin
might have aneuploidy, facilitating the
choice of which fetus to be tested
genetically.
Conclusions
The results of an algorithm for cfDNA
testing in twin pregnancies taking into
account maternal age and fetal fraction is
presented. This large multicenter study
confirms that cfDNA testing is the most
accurate screening test for trisomy 21 in
twin pregnancies, and the failure rate
was reassuringly very low (0.31%); this
screening performance of NIPT in twin
pregnancies seems similar to that in
singletons. The predictive accuracy for
trisomies 18 and 13 may be less. The
greater likelihood of trisomy 21 in mul-
tiple pregnancy, higher FPR of other
screening approaches, higher likelihood
of being offered invasive testing, and the
greater likelihood of complications ofinvasive testing10,35 all mean that cfDNA
has an important role to play in
screening for trisomies in twins. In our
view, such testing has the potential to
overcome many of these complex issues
and, given the much lower FPR (and
high DR) in combination with the rela-
tively low incidence of twin pregnancy,
should be considered as a primary
screening test in twins. n
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SUPPLEMENTAL FIGURE 1
Study flowchart of participants recruited at or after 20 weeks’ gestation
The study enrolled 194 twin pregnancies at 20 weeks’ gestation or beyond; 189 (130 dichorionic
and 59 monochorionic) had results available for analysis and 187 were included in the final analysis.
T18, trisomy 18; T21, trisomy 21.
Khalil et al. Cell-free DNA in twins. Am J Obstet Gynecol 2021.
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SUPPLEMENTAL FIGURE 2
Study flowchart of participants recruited prior to 20 weeks’ gestation
The study enrolled 809 twin pregnancies before 20 weeks’ gestation; 772 (555 dichorionic and 217
monochorionic) had results available for analysis and 771 were included in the final analysis.
T13, trisomy 13.
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SUPPLEMENTAL TABLE
Existing screening studies using cfDNA in twins for the detection of trisomies 21, 18, and 13













method GA (wk) Population
Lau et al,19 2013 Trisomy 21 12 2 (16.7) 1 — — 100 MPSS 13 (11e20) High risk
Huang et al,20 2014 Trisomies 21 and 18 189 33 (17.5) 9 2 — 100 MPSS 19 (11e36) High risk
Tan et al,21 2016 Trisomy 21 560 18 (3.2)a 4 — — 90 MPSS 12 (11e28) Mixture
Du et al,22 2017 Trisomy 21 92 39 (42.4) 2 — — 100 MPSS 18 (14e23) High risk
Le Conte et al,23 2018 Trisomies 21, 18, and 13 418 86 (20.6) 3 1 0 85 MPSS 16 (10e35) Mixture
Yang et al,24 2018 Trisomies 21 and 18 432 95 (22.0) 4 1 — 91 MPSS >9 Mixture
Yu et al,25 2019 Trisomies 21, 18, and 13 1157 308 (26.6) 16 4 1 99 MPSS 18 (8e30) Mixture
Gil et al,26 2019 Trisomies 21, 18, and 13 997 143 (14.3) 17 10 2 94 Targeted 11 (10e14) Mixture
Garshasbi et al,27 2020 Trisomies 21 and 18 443 N/A 3 1 — 100 MPSS >9 Mixture
Motevasselian et al,28
2020
Trisomies 21, 18, and 13 356 76 (21.3)a 2 2 1 100 MPSS 15þ4 d (5 d) Mixture
He et al,29 2020 Trisomy 21 141 39 (27.7)a 1 — — 100 MPSS 16.1 (10e23) Mixture
Our study Trisomies 21, 18, and 13 958 276 (28.8) 13 2 1 96 NGS 14.1 (12.7e18.7) Mixture
Numbers reported are those after exclusion of cases without cfDNA test result or pregnancy outcome.
GA is given as mean (range), mean (SD) or actual value.
cfDNA, cell-free DNA, GA, gestational age; MPSS; massively parallel signature sequencing; NGS, next generation sequencing.
a Value in original sample before exclusion for failed results and no follow-up.
Khalil et al. Cell-free DNA in twins. Am J Obstet Gynecol 2021.
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